Sorafenib is an anticancer drug approved for the treatment of liver and kidney cancers. It works by targeting proteins involved in cancer growth and by inhibiting the development of the blood vessels that tumors need to grow and spread. In laboratory studies and in some patients, it has been studied for the treatment of tumors in the brain.
In this study, researchers want to find the highest dose of sorafenib that can be given safely with whole brain radiation therapy in patients with breast cancer that has metastasized to the brain. Investigators will also observe the preliminary effectiveness of the combination of sorafenib and whole brain radiation for treating these patients.
Some patients may be asked to concurrently participate in protocol 12-039 (a PET imaging protocol).